Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience

Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated with that modality in five oncology centers. We recorded therap...

Full description

Bibliographic Details
Main Authors: Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Mirosława Puskulluoglu, Joanna Lompart, Manuela Las-Jankowska, Katarzyna Krawczak, Ewa Wrona, Lech Zaręba, Justyna Żubrowska, Jerzy Walocha, Stanisława Bazan-Socha, Marek Ziobro
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Biomedicines
Subjects:
melanoma
immunotherapy
real-life data
nivolumab and ipilimumab
adverse events
Online Access:https://www.mdpi.com/2227-9059/10/10/2528

Internet

https://www.mdpi.com/2227-9059/10/10/2528

Similar Items